356 related articles for article (PubMed ID: 37507762)
21. A COP1-GATA2 axis suppresses AR signaling and prostate cancer.
Shen T; Dong B; Meng Y; Moore DD; Yang F
Proc Natl Acad Sci U S A; 2022 Oct; 119(43):e2205350119. PubMed ID: 36251994
[TBL] [Abstract][Full Text] [Related]
22. Epigenetic Reprogramming with Antisense Oligonucleotides Enhances the Effectiveness of Androgen Receptor Inhibition in Castration-Resistant Prostate Cancer.
Xiao L; Tien JC; Vo J; Tan M; Parolia A; Zhang Y; Wang L; Qiao Y; Shukla S; Wang X; Zheng H; Su F; Jing X; Luo E; Delekta A; Juckette KM; Xu A; Cao X; Alva AS; Kim Y; MacLeod AR; Chinnaiyan AM
Cancer Res; 2018 Oct; 78(20):5731-5740. PubMed ID: 30135193
[TBL] [Abstract][Full Text] [Related]
23. Combination therapy with androgen receptor N-terminal domain antagonist EPI-7170 and enzalutamide yields synergistic activity in AR-V7-positive prostate cancer.
Hirayama Y; Tam T; Jian K; Andersen RJ; Sadar MD
Mol Oncol; 2020 Oct; 14(10):2455-2470. PubMed ID: 32734688
[TBL] [Abstract][Full Text] [Related]
24. Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201).
Borgmann H; Lallous N; Ozistanbullu D; Beraldi E; Paul N; Dalal K; Fazli L; Haferkamp A; Lejeune P; Cherkasov A; Gleave ME
Eur Urol; 2018 Jan; 73(1):4-8. PubMed ID: 28851578
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of protein kinase C/Twist1 signaling augments anticancer effects of androgen deprivation and enzalutamide in prostate cancer.
Shiota M; Yokomizo A; Takeuchi A; Imada K; Kashiwagi E; Song Y; Inokuchi J; Tatsugami K; Uchiumi T; Naito S
Clin Cancer Res; 2014 Feb; 20(4):951-61. PubMed ID: 24352647
[TBL] [Abstract][Full Text] [Related]
26. The DNA/RNA helicase DHX9 contributes to the transcriptional program of the androgen receptor in prostate cancer.
Chellini L; Pieraccioli M; Sette C; Paronetto MP
J Exp Clin Cancer Res; 2022 May; 41(1):178. PubMed ID: 35590370
[TBL] [Abstract][Full Text] [Related]
27.
Özgür E; Celik AI; Darendeliler E; Gezer U
Anticancer Res; 2017 Jul; 37(7):3631-3637. PubMed ID: 28668854
[TBL] [Abstract][Full Text] [Related]
28. Niclosamide and Bicalutamide Combination Treatment Overcomes Enzalutamide- and Bicalutamide-Resistant Prostate Cancer.
Liu C; Armstrong CM; Lou W; Lombard AP; Cucchiara V; Gu X; Yang JC; Nadiminty N; Pan CX; Evans CP; Gao AC
Mol Cancer Ther; 2017 Aug; 16(8):1521-1530. PubMed ID: 28500234
[TBL] [Abstract][Full Text] [Related]
29. Continued androgen signalling inhibition improves cabazitaxel efficacy in prostate cancer.
Mout L; van Royen ME; de Ridder C; Stuurman D; van de Geer WS; Marques R; Buck SAJ; French PJ; van de Werken HJG; Mathijssen RHJ; de Wit R; Lolkema MP; van Weerden WM
EBioMedicine; 2021 Nov; 73():103681. PubMed ID: 34749299
[TBL] [Abstract][Full Text] [Related]
30. Second generation androgen receptor antagonists and challenges in prostate cancer treatment.
Chen Y; Zhou Q; Hankey W; Fang X; Yuan F
Cell Death Dis; 2022 Jul; 13(7):632. PubMed ID: 35864113
[TBL] [Abstract][Full Text] [Related]
31. Allosteric inhibition of HSP70 in collaboration with STUB1 augments enzalutamide efficacy in antiandrogen resistant prostate tumor and patient-derived models.
Xu P; Yang JC; Ning S; Chen B; Nip C; Wei Q; Liu L; Johnson OT; Gao AC; Gestwicki JE; Evans CP; Liu C
Pharmacol Res; 2023 Mar; 189():106692. PubMed ID: 36773708
[TBL] [Abstract][Full Text] [Related]
32. Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9
Wang R; Sun Y; Li L; Niu Y; Lin W; Lin C; Antonarakis ES; Luo J; Yeh S; Chang C
Eur Urol; 2017 Nov; 72(5):835-844. PubMed ID: 28528814
[TBL] [Abstract][Full Text] [Related]
33. RELA is sufficient to mediate interleukin-1 repression of androgen receptor expression and activity in an LNCaP disease progression model.
Thomas-Jardin SE; Dahl H; Kanchwala MS; Ha F; Jacob J; Soundharrajan R; Bautista M; Nawas AF; Robichaux D; Mistry R; Anunobi V; Xing C; Delk NA
Prostate; 2020 Feb; 80(2):133-145. PubMed ID: 31730277
[TBL] [Abstract][Full Text] [Related]
34. Effect of Monoamine oxidase A (MAOA) inhibitors on androgen-sensitive and castration-resistant prostate cancer cells.
Gaur S; Gross ME; Liao CP; Qian B; Shih JC
Prostate; 2019 May; 79(6):667-677. PubMed ID: 30693539
[TBL] [Abstract][Full Text] [Related]
35. Discovery of a Novel Bifunctional Steroid Analog, YXG-158, as an Androgen Receptor Degrader and CYP17A1 Inhibitor for the Treatment of Enzalutamide-Resistant Prostate Cancer.
Wang A; Luo X; Meng X; Lu Z; Chen K; Yang Y
J Med Chem; 2023 Jul; 66(14):9972-9991. PubMed ID: 37458396
[TBL] [Abstract][Full Text] [Related]
36. TACC2 is an androgen-responsive cell cycle regulator promoting androgen-mediated and castration-resistant growth of prostate cancer.
Takayama K; Horie-Inoue K; Suzuki T; Urano T; Ikeda K; Fujimura T; Takahashi S; Homma Y; Ouchi Y; Inoue S
Mol Endocrinol; 2012 May; 26(5):748-61. PubMed ID: 22456197
[TBL] [Abstract][Full Text] [Related]
37. Electronic effect-dependent intramolecular non-covalent interactions on the activity of 4,4-dimethylimidazolidin-2-one pharmacophore-based androgen receptor antagonists.
Yaragani M; Yadlapalli P; Raghavan S; Giridhar T; Mandava VBR; Singh RV; Kottapalli RP; Chinnusamy S
Chem Biol Drug Des; 2023 Mar; 101(3):614-625. PubMed ID: 36198102
[TBL] [Abstract][Full Text] [Related]
38. Glucocorticoid receptor activity contributes to resistance to androgen-targeted therapy in prostate cancer.
Isikbay M; Otto K; Kregel S; Kach J; Cai Y; Vander Griend DJ; Conzen SD; Szmulewitz RZ
Horm Cancer; 2014 Apr; 5(2):72-89. PubMed ID: 24615402
[TBL] [Abstract][Full Text] [Related]
39. Androgen receptor as a driver of therapeutic resistance in advanced prostate cancer.
Kahn B; Collazo J; Kyprianou N
Int J Biol Sci; 2014; 10(6):588-95. PubMed ID: 24948871
[TBL] [Abstract][Full Text] [Related]
40. The tumor suppressor ING1b is a novel corepressor for the androgen receptor and induces cellular senescence in prostate cancer cells.
Esmaeili M; Jennek S; Ludwig S; Klitzsch A; Kraft F; Melle C; Baniahmad A
J Mol Cell Biol; 2016 Jun; 8(3):207-20. PubMed ID: 26993046
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
